TG Therapeutics Inc
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +30.8% | -51.7% | +77.8% | -14.1% | +95.0% | +283.8% | -39.3% | -49.0% | +70.3% | +75.3% | +84.1% | |
| – | +1.9% | -41.5% | +83.5% | -15.3% | +88.7% | +310.1% | -45.9% | -49.2% | +88.9% | +78.1% | +11.4% | |
| – | -1.2% | -54.5% | +126.6% | -26.0% | +168.5% | +391.3% | -46.0% | -65.8% | -9.2% | +93.6% | -56.0% | |
| – | +29.9% | -56.1% | +88.6% | -18.9% | +104.1% | +331.1% | -48.0% | -48.6% | +34.5% | +43.0% | -54.4% | |
| – | +117.5% | -54.9% | +29.4% | -12.4% | – | – | – | -100.0% | – | +152.8% | +136.6% | |
| – | -363.2% | – | +42.0% | +21.9% | – | – | – | – | – | +177.4% | +13.7% | |
| – | +131.5% | +596.4% | -24.4% | +1.2% | +12.4% | +70.6% | +24.7% | -48.8% | – | – | – | |
| – | +0.0% | +0.0% | +0.0% | 0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | – | |
| – | -0.1% | +0.1% | +0.0% | – | – | – | – | – | – | – | – | |
| – | +30.8% | -51.7% | +77.8% | -38.8% | +108.8% | -14.6% | +34.0% | -5.3% | +25.3% | +110.1% | +16.9% | |
| – | +105.6% | +60.3% | +65.6% | +39.0% | +117.3% | +3.7% | -25.3% | -18.6% | +1.0% | +68.8% | +69.6% | |
| – | -23.1% | -67.4% | +85.3% | -47.5% | +2,311.9% | +1,375.7% | -89.9% | -34.5% | -8.5% | -20.0% | -9.8% | |
| – | +134.1% | +63.4% | +69.5% | +40.6% | -17.4% | +23.2% | +38.6% | -18.1% | -8.4% | +51.5% | +84.4% | |
| – | – | – | – | – | – | -73.4% | +765.6% | +6.5% | +40.7% | +144.1% | +0.5% | |
| – | +26.8% | -64.7% | +86.8% | -64.1% | +60.7% | +1,244.9% | -54.3% | -75.3% | +174.0% | +38.5% | +191.4% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +34.0% | +7.4% | +26.6% | +21.6% | +17.1% | +30.5% | +14.6% | +2.4% | +9.7% | +8.0% | +0.7% |
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.